linjc16/ctgov huggingface dataset:
Are There Different Objective Fixation Disparity Values for Two Different Test Paradigms

Study Overview
=================
Brief Summary
-----------------
In optometry, binocular coordination is measured subjectively. The result is subjective fixation disparity. In research different experiments have proven, that subjective and objective fixation disparity are different. A binocular eyetracker has to be calibrated. There are two well known calibration methods: associated and dissociated calibration. Objective fixation disparity is measured in arcMin. Therefore, the precision of the eyetracker plays a crucial role. Now, the investigators try to compare dissociated calibration with polarized filters and associated calibration under different test paradigms.

Official Title
-----------------
Are There Different Objective Fixation Disparity Values for Two Different Test Paradigms: Similar to Reading Dot Presentation and Text Reading? - How This Phenomenon Can be Explained

Conditions
-----------------
Vision Disparity

Intervention / Treatment
-----------------
* Other: different test paradigms


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: VA without glasses/contact lenses 0.63 Accurate accommodation on 57cm Exclusion Criteria: Tiredness at day of investigation Presbyopia Alcohol or drug abuse No eye related pathology No strabism No known epilepsy-attack in family

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: different test paradigms|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fixation disparity in arcMin during a reading and reading related dot paradigm | With an eyetracker fixation disparity will be measured on an objective way. The scale will be arcMin and test paradigm a reading tast and a dot task, similar to reading. | Through study completion, up to 10 months |
The Impact of Problem-Based Learning (PBL) and Lecturing

Study Overview
=================
Brief Summary
-----------------
The present study aimed to compare the effect of education through problem-based learning (PBL) or lectures on behavior, attitude and learning of nursing students.

Detailed Description
-----------------
A total of 40 second-year nursing students participated: 20 students in the PBL group and 20 students in the traditional lecture (control) group. The students underwent a one-semester course using the two methods of education

Official Title
-----------------
The Impact of Problem-Based Learning (PBL) and Lecturing on the Behavior and Attitudes of Iranian Nursing Students: a Randomised Controlled Trial (RCT)

Conditions
-----------------
Learning

Intervention / Treatment
-----------------
* Behavioral: PBL


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Students must not have been exposed to PBL Exclusion Criteria: Biased and specific students

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 23 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 2<br> | Behavioral: PBL<br> <br> |
| No Intervention: A, 2, III<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Problem-based learning (PBL), lecture, nursing, education, none of students had any prior exposure to PBL
S90652 in Paediatric Hypertension

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to assess the acceptability, safety and pharmacokinetics and effects on blood pressure of a paediatric formulation of perindopril given in hypertensive children

Official Title
-----------------
Acceptability, Safety, Pharmacokinetics and Effects on Blood Pressure of a Daily Dose of 0.025 to 0.135 Milligram Per Kilogram of S90652, a Paediatric Formulation of Perindopril, in 2-16 Years Old Hypertensive Children - 3 Month Study

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Perindopril


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hypertensive children Exclusion Criteria: Renal failure Unstable renal function Hyperkaliemia

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Perindopril|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety assessed from the patient's (parents) complaints and the clinical follow-up |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acceptability, efficacy, pharmacokinetics |  |  |
Intrauterine Injection of HCG and Implantation Rate

Study Overview
=================
Brief Summary
-----------------
The study aims to examine the effect of intrauterine injection of HCG on pregnany rate in women undergoing IVF treatment.

Official Title
-----------------
The Effect of HCG Injection to the Uterine Cavity on Pregnancy Rate in Women Undergoing IVF Treatment

Conditions
-----------------
Pregnancy Rate, Implantation Rate

Intervention / Treatment
-----------------
* Drug: HCG injection
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women undergoing IVF treatment Exclusion Criteria: > 40 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HCG administration<br>Intrauterine HCG injection | Drug: HCG injection<br> <br> |
| Placebo Comparator: Placebo<br>G2 Medium | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pregnancy rate |  | 1 year |
A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension

Study Overview
=================
Brief Summary
-----------------
SAFETY EXTENSION STUDY TO THE CORE STUDY CVAH631C2301

Official Title
-----------------
A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: SUCCESSFUL COMPLETION OF STUDY CVAH631C2301 - Exclusion Criteria: NONE

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events and serious adverse events at each study visit for 54 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in diastolic blood pressure from baseline after 54 weeks |  |  | 
| Change from baseline in systolic blood pressure from baseline after 54 weeks |  |  | 
| Change from baseline in standing diastolic and systolic blood pressure after 54 weeks |  |  | 
| Hematology and blood chemistries up to 54 weeks |  |  | 
| Physical condition including pregnancy, pulse and weight at each study visit |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HYPERTENSION, VALSARTAN
Energy Expenditure Responses to Acute Exercise in Older Women (Calorie Expenditure and Exercise)

Study Overview
=================
Brief Summary
-----------------
In older, normal-weight women (60-75 yrs, BMI=18-28 kg/m2), an acute bout of higher-intensity (60% of maximum effort) aerobic exercise, in comparison to an isocaloric bout of lower-intensity (45% of maximum effort) exercise (caloric expenditure of 3.5 kcal/kg body weight for both), will result in differential: decline in non-exercise activity calorie expenditure in the subsequent 48 hours after exercise; increase in resting metabolic rate 48 hours after exercise; increase in serum free triiodo-L-thyronine (free T3) concentrations immediately following exercise; decline from pre-exercise in plasma leptin and serum free T3 concentrations 48 hours after exercise.

Official Title
-----------------
Energy Expenditure Responses to Acute Exercise in Older Women

Conditions
-----------------
Aging

Intervention / Treatment
-----------------
* Other: exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women Age 60-75 years normal weight Weight-stable (± 5%) within the previous 3 months Non-smoking for last year Able to provide own transportation to study visits Not currently involved in any other research study Willing and able to participate in all aspects of the trial including research testing Willing to give informed consent to participate Exclusion Criteria: Self-reported significant cardiovascular disease Other self-reported medical conditions such as diabetes, chronic or recurrent respiratory conditions, active cancer, musculoskeletal disease Medications known to affect exercise performance or metabolism Excess caffeine use (> 500mg/day) Any self-reported contraindications to exercise Clinical depression Abnormal cognitive function -

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: exercise|exercise sessions at 45% and 60% of maximum effort|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| non-exercise activity calorie expenditure |  | 2 days after exercise sessions | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| resting metabolic rate |  | 2 days after exercise sessions | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
older, NEAT, exercise, RMR, energy expenditure
Analysis of Adverse Events in Anesthesia Using Artificial Intelligence

Study Overview
=================
Brief Summary
-----------------
The interest of health databases in anesthesia is no longer to be demonstrated. The aim of this research was to develop a natural language processing approach to establish a classification of adverse events observed during the perioperative period and to facilitate their analysis: The main objective of the study was to identify what a naïve unsupervised model would discover based on Adverse Event (AE) descriptions. Our second goal was to identify apparently unrelated events whose combination could favor the occurrence of an AE

Official Title
-----------------
Analysis of ADVerse evENTs in Anesthesia Using ARtificial IntelligencE

Conditions
-----------------
Allergic Reaction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Minors and adults having had an allergic reaction associated with care Having had an adverse event reported by an anesthetist between January 01, 2009 and June 30, 2020 Exclusion Criteria: - Patient not meeting the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of a natural language processing approach to establish a classification of adverse events observed during the perioperative period and to facilitate their analysis. | The aim of this research was to develop a natural language processing approach to establish a classification of adverse events observed during the perioperative period and to facilitate their analysis: The main objective of the study was to identify what a naïve unsupervised model would discover based on Adverse Event (AE) descriptions. Our second goal was to identify apparently unrelated events whose combination could favor the occurrence of an AE | Files analysed retrospectively from January 01, 2009 to June 30, 2020 will be examined] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Allergic Reaction, Adverse events, Health database, Natural Language Processing
Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer

Study Overview
=================
Brief Summary
-----------------
In the proposed project the investigators will asses whether changes in expression of selected circulating microRNAs in serum could comprise a sensitive and specific biomarker of cardiotoxicity in cancer patients treated with anthracyclines based chemotherapy.

Detailed Description
-----------------
Blood will be taken before anthracycline based chemotherapy administration at the middle of anthracycline treatment (before 3rd and/or 5th cycle of drugs infusion) after anthracycline chemotherapy cessation 6 months after chemotherapy cessation if an end point occurs 12 months after chemotherapy cessation if an end point occurs Echocardiography will be performed before anthracycline based chemotherapy administration after anthracycline based chemotherapy cessation 6 months after anthracycline based chemotherapy cessation 12 months after anthracycline based chemotherapy cessation if no end point was observed earlier The investigators will perform high-throughput miRNA(microRNA) expression profiling of serum samples - called training set. Training set will consist of sera of 30 patients who has reached an end point. Training set will be sequenced using next generation sequencing. Training set will be used to derive a miRNA signature capable of separating early cardiotoxicity patients from healthy ones. MiRNA signature will be validated using validation set.

Official Title
-----------------
Circulating microRNAs as a Novel Biomarker of Early Cardiotoxicity in Breast Cancer Patients Treated With Anthracyclines

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18-70 stage I-III TNM (Tumor Node Metastases) Exclusion Criteria: second or next cancer (except for basal cell skin cancer and CIN) previously treated with chemotherapy previously treated with radiotherapy acute myocardial infarction heart failure cardiomyopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiotoxicity events according to CREC (Cardiac Review and evaluation Committee) criteria | either a cardiomyopathy with decreased left ventricular ejection fraction (LVEF), a reduction of LVEF ≥5% to <55% with symptoms of heart failure (e.g. orthopnoea and paroxysmal nocturnal dyspnoea, elevated jugular venous pressure, S3 gallop, Hepatojugular reflux, tachycardia), or an asymptomatic reduction of LVEF ≥10% to <55% | up to 76 weeks after chemotherapy conclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
breast cancer, anthracyclines, cardiotoxicity, circulating microRNA, biomarker, serum, anthracyclines based chemotherapy
Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals

Study Overview
=================
Brief Summary
-----------------
Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders. A growing body of evidence, comprising a great deal of cross-sectional studies and several prospective ones, also indicates that hyperuricemia is associated with increased prevalence, incidence, and disease severity of non-alcoholic fatty liver disease (NAFLD). Capitalizing on a cohort study in China, the investigators are aimed to assess the associations of SUA trajecteries with remission of NAFLD in NAFLD individuals and examined whether the association differs across subpopulations.

Detailed Description
-----------------
A cohort study was conducted to evaluate the relationship between the SUA trajecteries and remission of NAFLD. The study enrolled employees who were attending their annual health examination. Furrhermore, the investigators are aimed to explore whether the association differs across subpopulations.

Official Title
-----------------
Assocaiton Between Uric Acid Trajecteries and Remission of Non-alcoholic Fatty Liver Disease (NAFLD) in NAFLD Individuals

Conditions
-----------------
Non-Alcoholic Fatty Liver Disease, Hyperuricemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >=18 years; agree to be enrolled in this study. Exclusion Criteria: those taking antihypertensive or antidiabetic agents, lipid-lowing agents, or hypouricemic agents; those with alcohol consumption greater than 140 g/week for men and 70 g/week for women; those with a history of other known causes of chronic liver disease such as viral hepatitis or autoimmune hepatitis, and those using hepatotoxic medications.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the severity fatty liver evaluated by hepatic ultrasonic examination | Hepatic ultrasonic examination was performed in all subjects by a trained ultrasonographist who was unaware of the clinical and laboratory data. Hepatic steatosis was diagnosed by characteristic echo patterns according to conventional criteria, such as the evidence of diffuse hyperechogenicity of the liver relative to the kidneys, ultrasound beam attenuation, and poor visualization of intrahepatic structures. | 2 years |
Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to determine the moxifloxacin aqueous penetration when dosing with a combination drug Vigadexa preoperatively in cataract patients.

Official Title
-----------------
Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Drug: Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Requires cataract surgery; Acceptable health status (medical history, physical, laboratory and ophthalmologic exams); Able to follow instructions and willing to attend all study visits; Other protocol-defined inclusion criteria may apply. Exclusion Criteria: Any known or suspected allergies/hypersensitivity to any of the investigational test product components; History of invasive intraocular surgery in the eye to be operated, within 4 months before enrollment; Use of medications, as specified in protocol; Severe dry eye syndrome; Use of contact lenses two days before surgery until the last visit; External eye disease, infection or inflammation of the eyes or eyelids; Excessive bleeding tendency; No vision in the eye not included in the study; Pregnant or breastfeeding; Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: VIGADEXA<br>Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution, 1 drop instilled in the study eye 2 days before surgery, followed by 1 drop instilled 4 times a day the day before surgery. On the day of surgery, 1 drop was instilled 60 minutes prior to the procedure. | Drug: Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution<br> <br> * Other names: Vigadexa®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Aqueous Humor Concentration of Moxifloxacin | A 0.150 milliliter sample of the aqueous humor was obtained during cataract surgery. The concentration of moxifloxacin was measured by a validated procedure using high performance liquid-spectrometry. | Day 3 (operative day) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aqueous Humor, Moxifloxacin, Vigadexa